THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Susan A Wood, PhD., President & CEO, VIDAVIDA, with its deep history in respiratory care and clinically-validated approach to AI imaging analysis, is at the vanguard of supporting physicians in tackling patient care challenges. “We have played a key role for over a decade in academic and industry clinical trials and are now applying leading expertise to support care delivery in health systems,” says Susan Wood, PhD., President and CEO of the company. VIDA provides evidence-based analysis that can aid in early detection, evaluation, and/or treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), asthma and now COVID-19.
VIDA’s AI-based lung analysis solution, LungPrint, takes a unique approach to evaluating patients with or at-risk of lung diseases. Leveraging comprehensive data from patient chest CTs, LungPrint is able to provide radiologists with a powerful blend of qualitative and quantitative reports that decrease highly complex chest CT read times by 35 percent, highlight areas that may require additional physician attention and offer rapid secondary validation of findings. The solution integrates with existing radiology workflows and yields actionable insights for both radiologists and pulmonologists.
“As LungPrint becomes part of the standard of care, we have the opportunity to support earlier detection of COPD and ILD, to provide precision reports for personalized treatment selection based on the presence of unique biomarkers and to monitor patients longitudinally for disease management,” says Susan. This helps to achieve the value-based care triple aim of improving the patient experience, enhancing quality of care and driving positive outcomes at lower overall cost.
We are a clinical AI company that is playing a key role in a number of academic and industry validation trials as well as care delivery in health systems
Some of the cost burden to the healthcare system has been driven by an inability to target the right drug to the right patient at the right time. Developing a drug from discovery to commercialization is a long and complex undertaking. Respiratory diseases bring an additional set of challenges to the process. “Because the clinical endpoints are generalized rather than being objective and repeatable, it is quite difficult to understand if a drug is working,” says Susan. VIDA supports clinical trials with services ranging from pre-clinical imaging consulting to data analysis and interpretation. “In our clinical trials, we use imaging-based biomarkers and depend on fewer subjects, and as a result, we accelerate the time to market of the drug,” she adds. More importantly, clients can easily understand if a particular molecule is likely to deliver the expected results in the early stages of drug development. This can help research teams define precise endpoints during clinical trials and potentially contribute to development of more personalized drugs. VIDA’s quality-controlled imaging service has been used in over 60 academic and industry clinical trials across 30 countries to date. These services are delivered from VIDA’s specialized core lab, operated with an ISO-13485 certified quality system.
In one VIDA case study of clinical application, a patient was diagnosed with severe asthma and treated accordingly but saw no improvement to his health. Revisiting the chest CT with LungPrint, the radiologist found evidence suggesting the patient had an alpha-1 antitrypsin deficiency that had led to COPD. Now empowered with more precise and accurate information, the treating physician ran a genetic test and re-evaluated the findings, then adjusted patient treatment to focus on the accurate underlying condition.
Company
VIDA
Management
Susan A Wood, PhD., President & CEO, VIDA
Description
VIDA, with its deep history in respiratory care and clinically-validated approach to AI imaging analysis, is at the vanguard of supporting physicians in tackling patient care challenges. The company provides evidence-based analysis that can aid in early detection, evaluation, and/or treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), asthma and now COVID-19. VIDA’s AI-based lung analysis solution, LungPrint, takes a unique approach to evaluating patients with or at-risk of lung diseases. Using the company’s offerings, organizations can easily understand if a particular molecule is likely to deliver the expected results in the early stages of drug development
VIDA News
Polarean Partners with VIDA to Streamline Adoption of Advanced MRI of the Lungs
DURHAM - Polarean (AIM: POLX), announced today it has partnered with VIDA Diagnostics (VIDA), a clinical imaging intelligence company providing medical imaging software solutions which manage the complexities of digital biomarkers. The companies are partnering to develop solutions that further enable the Polarean xenon 129 MRI platform to accelerate clinical and research use.
VIDA has empowered over 1,000 clinical and research sites worldwide with its cloud-native AI-enabled imaging management platform. This platform drives standardization and efficiency improvements in the operations of clinical trial imaging. It incorporates a unique orchestration engine that facilitates the integration and optimization of multimodality clinical algorithms. This, in turn, makes new high-quality imaging biomarkers more accessible to researchers, clinical trials, and their integration into clinical care workflows.
The collaboration between Polarean and VIDA aims to:
1. Facilitate the integration of the xenon 129 MRI workflow into the clinical continuum of care.
2. Establish a clinical trial network for pharmaceutical-sponsored drug and device development, utilizing standardized xenon 129 MR image acquisition and data-sharing methods.
3. Create automated image processing workflows and algorithms.
These new products and services will expand access to xenon 129 MRI as a lung imaging service and investigate new indications and biomarkers in broader populations with unmet medical needs. Additionally, through this collaboration, both companies will foster new research collaborations and enhance the opportunities available to their lung imaging customers.
“Polarean continues to cultivate partnerships with entities that enhance our core capabilities. We are excited to form this partnership with VIDA, a world-renowned organization in the field of lung imaging software platform solutions and biomarker development, to capitalize on their complementary expertise,” said Christopher von Jako, Ph.D., CEO of Polarean. “Furthermore, this partnership perfectly aligns with our objective of extending the reach of XENOVIEW™ MRI, to provide tools to physicians that treat patients suffering from chronic lung disease.”
“VIDA and Polarean are natural partners. Both companies share a goal of empowering providers with advanced medical imaging solutions to enhance clinical decisions and accelerate bringing new therapies to patients,” said Susan Wood, Ph.D., CEO of VIDA. “We are excited at the prospect of expanding our imaging platform portfolio through our collaboration with Polarean, thereby introducing pioneering MRI-based lung imaging biomarkers.”
Polarean has recently introduced XENOVIEW, an inhaled MRI hyperpolarized contrast agent that is the first and only of its kind. XENOVIEW utilizes xenon Xe 129 in a hyperpolarized state to enable the visualization of lung ventilation. This innovative technology is grounded in MRI, ensuring that patients are not exposed to ionizing radiation or the associated health risks.
The administration of XENOVIEW, created through the Polarean HPX hyperpolarization system, is a quick and efficient process, taking only 10-15 seconds during a single breath-hold MRI procedure. XENOVIEW is specifically indicated for use in MRI examinations for assessing lung ventilation in both adult and pediatric patients aged 12 years and older. It is important to note that XENOVIEW has not undergone evaluation for use in lung perfusion imaging.